Westwood Holdings Group Inc. Acquires Shares of 3,121 GlaxoSmithKline plc (NYSE:GSK)

Westwood Holdings Group Inc. acquired a new stake in shares of GlaxoSmithKline plc (NYSE:GSK) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 3,121 shares of the pharmaceutical company’s stock, valued at approximately $125,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Morgan Stanley lifted its stake in shares of GlaxoSmithKline by 5.8% in the 2nd quarter. Morgan Stanley now owns 3,845,882 shares of the pharmaceutical company’s stock valued at $153,912,000 after purchasing an additional 212,166 shares during the period. HBK Sorce Advisory LLC lifted its stake in shares of GlaxoSmithKline by 34.8% in the 2nd quarter. HBK Sorce Advisory LLC now owns 11,753 shares of the pharmaceutical company’s stock valued at $509,000 after purchasing an additional 3,033 shares during the period. Sio Capital Management LLC lifted its stake in shares of GlaxoSmithKline by 44.8% in the 2nd quarter. Sio Capital Management LLC now owns 379,500 shares of the pharmaceutical company’s stock valued at $15,188,000 after purchasing an additional 117,500 shares during the period. Assetmark Inc. lifted its stake in shares of GlaxoSmithKline by 99.0% in the 2nd quarter. Assetmark Inc. now owns 7,208 shares of the pharmaceutical company’s stock valued at $288,000 after purchasing an additional 3,586 shares during the period. Finally, Gladstone Institutional Advisory LLC acquired a new position in shares of GlaxoSmithKline in the 2nd quarter valued at $327,000. Hedge funds and other institutional investors own 11.12% of the company’s stock.

Several research firms recently issued reports on GSK. ValuEngine cut shares of GlaxoSmithKline from a “hold” rating to a “sell” rating in a research note on Tuesday, September 10th. Jefferies Financial Group reiterated a “buy” rating on shares of GlaxoSmithKline in a research note on Thursday, August 29th. Cowen reiterated a “hold” rating and issued a $45.00 target price on shares of GlaxoSmithKline in a research note on Monday, June 10th. Societe Generale upgraded shares of GlaxoSmithKline from a “sell” rating to a “buy” rating in a research note on Tuesday, September 3rd. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, August 13th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $41.79.



NYSE GSK traded up $0.15 on Tuesday, hitting $42.07. The company had a trading volume of 100,061 shares, compared to its average volume of 1,976,847. The company has a market capitalization of $103.83 billion, a PE ratio of 13.31, a PEG ratio of 2.00 and a beta of 0.70. The company’s fifty day moving average price is $41.07 and its 200-day moving average price is $40.63. The company has a debt-to-equity ratio of 7.86, a current ratio of 0.71 and a quick ratio of 0.48. GlaxoSmithKline plc has a 12-month low of $36.41 and a 12-month high of $42.49.

GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.64 by $0.14. The company had revenue of $10.04 billion during the quarter, compared to analyst estimates of $9.55 billion. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. On average, sell-side analysts anticipate that GlaxoSmithKline plc will post 2.95 EPS for the current year.

In related news, Director Plc Glaxosmithkline purchased 177,777 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was bought at an average price of $45.00 per share, with a total value of $7,999,965.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 10.00% of the stock is currently owned by insiders.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

See Also: How to interpret Moving Average Convergence Divergence (MACD)

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.